Skip to content
Close
Contact Us
Contact Us

ISGD CLINICAL TRIALS SUMMIT 2026

November 12-16, 2026
Galveston, Texas

 PATHWAYS TO PROGRESS: THE INAUGURAL CLINICAL TRIALS INNOVATION SUMMIT 

 

Add to Calendar

UNITING VISION, SCIENCE, AND PARTNERSHIP TO ACCELERATE KIDNEY CURES

The 2026 ISGD Clinical Trials Innovation Summit will serve as a global hub for clinical trialists, nephrologists, and other stakeholders committed to transforming the future of kidney disease research. Convening world-renowned keynote speakers and innovative collaborative formats, the Summit is designed to accelerate innovation, catalyze collaboration, and design solutions to the key challenges of clinical trials in glomerular diseases and beyond.

This inaugural Clinical Trials Innovation Summit will spotlight the most pressing challenges in clinical trial design, patient stratification, new drug target identification, and regulatory endpoints. Featuring a thoughtfully curated program with panel discussions, speed networking, and interactive workshops, attendees will benefit from practical training sessions, robust participation opportunities for emerging investigators, and focused cross-stakeholder breakout groups. The Summit organizers aim to produce not only a meaningful and informative experience, but a roadmap for improved clinical trials to be published as a product of the meeting. The conference design emphasizes inclusivity, balancing academic, industry, regulatory, and patient advocacy perspectives to ensure actionable solutions for diverse and global kidney patient populations.

JOIN THE LIST

Sign up to receive updates on the conference program, registration, and abstract submission opportunities!
KEEP ME UPDATED

ABOUT THE ORGANIZERS

Hosted by the International Society of Glomerular Disease (ISGD) in partnership with the renowned nephrology and clinical trials leadership team of the University of Texas Medical Branch, the Clinical Trials Innovation Summit delivers an expertly curated platform that fuses scientific rigor, operational excellence, and hands-on engagement for attendees.

ISGD’s recent stewardship of the acclaimed 15th International Podocyte Conference, praised by faculty and attendees for its seamless integration of basic, translational, and clinical content as well as unparalleled community building, is a direct template for the Clinical Trials Innovation Summit. The Podocyte Conference’s sold-out attendance, sophisticated logistics, and highly rated science underscore ISGD’s ability to convene world leaders, innovate session formats, and maximize value for all participants.

ISGD logo 400x400
Read More
HOSTInternational Society of Glomerular Disease

ISGD is a global professional society building the future of glomerular medicine by bringing together clinicians, researchers, and other experts to advance research; support the development of specialists and centers of excellence; and enable access to timely and suitable treatments.

Read More
Shikha Wadhwani
Read More
MEETING CHAIRShikha Wadhwani, MD, MS
University of Texas Medical Branch
Associate Professor of Nephrology
Vice Chair of Internal Medicine, Clinical Research & Director, Nephrology Clinical Trials
Read More
Jochen Reiser
Read More
MEETING CHAIRJochen Reiser, MD, PhD
President of the University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System
Professor of Nephrology
 
Read More
UTMB 400x400
Read More
HOSTUniversity of Texas Medical Branch

UTMB opened in 1891 as the nation’s first public medical school and hospital under unified leadership. What began as one hospital and medical school building in Galveston is now a major academic health sciences center of global influence; a world-renowned research enterprise; and a growing, comprehensive health system with hospitals on four campuses and a network of clinics.

Read More
iStock-840465932-1

SPONSORSHIP OPPORTUNITIES

Join us in shaping the future of kidney clinical trials—your partnership will enable the Summit to deliver unique networking, professional development, and educational opportunities, while directly supporting the transformation of breakthrough science into improved patient outcomes.

LEARN MORE